

**AMENDMENTS TO THE CLAIMS**

Pursuant to 37 C.F.R. §1.121 the following is a complete listing of the claims of the present application. In this set of claims, please amend the claims as follows. The following listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1. (Previously presented) An isolated nucleic acid comprising a nucleotide sequence selected from the group consisting of:
    - (a) a nucleotide sequence set forth in SEQ ID NO: 1;
    - (b) a nucleotide sequence encoding a polypeptide comprising an amino acid sequence as set forth in SEQ ID NO: 2; and
    - (c) a nucleotide sequence fully complementary to (a) or (b).
  - 2-3. (Canceled)
  4. (Previously presented) A vector comprising the nucleic acid of claim 1.
  5. (Previously presented) An isolated recombinant host cell comprising the vector of claim 4.
  6. (Previously presented) The host cell of claim 5 that is a eukaryotic cell.
  7. (Previously presented) The host cell of claim 5 that is a prokaryotic cell.
  8. (Previously presented) A process of producing a CD20/IgE-receptor like polypeptide comprising culturing the host cell of claim 5 under suitable conditions to express a CD20/IgE-receptor like polypeptide encoded by the nucleic acid.
  9. (Canceled)
  10. (Previously presented) The process of claim 8, wherein the vector further comprises a heterologous promoter operatively linked to the nucleotide sequence encoding the CD20/IgE-receptor like polypeptide.
- 11-50. (Canceled)

51. (Previously presented) A composition comprising a nucleic acid of claim 1 and a pharmaceutically acceptable formulating agent.

52. (Previously presented) A composition of Claim 51 wherein said nucleic acid is contained in a viral vector.

53. (Previously presented) A viral vector comprising a nucleic acid of claim 1.

54. (Previously presented) A fusion polypeptide comprising an amino acid sequence encoded by the nucleic acid sequence of claim 1 fused to a heterologous amino acid sequence.

55. (Previously presented) The fusion polypeptide of claim 54 wherein the heterologous amino acid sequence is an IgG constant domain or fragment thereof.

56-69. (Canceled)

70. (Previously presented) A nucleic acid according to claim 1 attached to a solid support.

71. (Canceled)

72. (Previously presented) The process of claim 8 further comprising isolating the polypeptide from the culture.

73. (New) An isolated nucleic acid comprising a nucleotide sequence set forth in SEQ ID NO: 1 for detecting the expression of agp-96614 messenger RNA in human testis cells.